| INTELLIA THERAPEUTICS |
| USA |
| Gesundheit |
| US45826J1051 / A2AG6H |
| 38I (Frankfurt) / NTLA (NASDAQ) |
| FRA:38I, ETR:38I, 38I:GR, NASDAQ:NTLA |
| - |
| https://www.intelliatx.co.. |
|
Intellia Therapeutics is a clinical-stage genome editing company focused on developing curative treatments using CRISPR/Cas9 technology. The company transforms medicine by permanently editing and correcting disease-associated genes within the human b..
>Volltext.. |
| 1462.74 Mio. EUR |
| 1206.79 Mio. EUR |
| 57.14 Mio. EUR |
| -350.17 Mio. EUR |
| -341.12 Mio. EUR |
| -3.06 EUR |
| 69.58 Mio. EUR |
| 116.44 Mio. EUR |
| -313.94 Mio. EUR |
| 4.92 |
| 35.81% |
| 29.74% |
| - |
| - |
| - |
| - |
| INTELLIA |
| 14.06.26 |